...
首页> 外文期刊>Journal of Nippon Medical School >Conversion Surgery for Metastatic Pancreatic Mucinous Carcinoma Responsive to Systemic Chemotherapy with Modified FOLFIRINOX: A Case Report
【24h】

Conversion Surgery for Metastatic Pancreatic Mucinous Carcinoma Responsive to Systemic Chemotherapy with Modified FOLFIRINOX: A Case Report

机译:改良FOLFIRINOX对全身化疗有反应的转移性胰腺黏液癌的手术治疗:一例报告

获取原文
           

摘要

We report a case of metastatic pancreatic-head mucinous carcinoma (with multiple lymph node and bone metastases) and review the relevant literature. Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) was useful for diagnosis, and a satisfactory outcome was achieved after systemic chemotherapy with FOLFIRINOX followed by resection of the primary lesion as conversion surgery. The patient was a 55-year-old man. Hematological findings included elevated serum tumor marker levels: CEA 12.7 ng/mL, DUPAN-2 400 U/mL. Findings from several imaging modalities and EUS-FNA confirmed a clinicopathological diagnosis of metastatic pancreatic mucinous carcinoma with multiple bone and lymph node metastases. Five courses of modified FOIFIRINOX ( m -FFX) were given as systemic chemotherapy, which had an antitumor effect. Subtotal stomach-preserving pancreaticoduodenectomy and extensive lymph-node dissection were thus performed. Histopathological analysis showed invasive ductal carcinoma, muc (pT3, pN1b, cM1). After surgery, the clinical course was notable for the absence of complications. Tegafur/gimeracil/oteracil (S-1) was started as maintenance adjuvant chemotherapy postoperatively, and no disease progression has been observed at 10 months after surgery.
机译:我们报告一例转移性胰头粘液癌(多发淋巴结和骨转移),并复习了相关文献。内镜超声引导下细针穿刺术(EUS-FNA)可用于诊断,在用FOLFIRINOX进行全身化学疗法并随后切除原发灶作为转换手术后,取得了令人满意的结果。病人是一个55岁的男人。血液学发现包括血清肿瘤标志物水平升高:CEA 12.7 ng / mL,DUPAN-2 400 U / mL。从几种成像方式和EUS-FNA的发现证实了具有多个骨和淋巴结转移的转移性胰腺粘液癌的临床病理诊断。进行了五个疗程的改良FOIFIRINOX(m -FFX)全身化疗,具有抗肿瘤作用。因此进行了次全胃保管胰十二指肠切除术和广泛的淋巴结清扫术。组织病理学分析显示浸润性导管癌,粘液性癌(pT3,pN1b,cM1)。手术后,临床过程中没有并发症。 Tegafur / gimeracil / oteracil(S-1)作为术后辅助化疗开始,在术后10个月未观察到疾病进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号